LdrB Toxin with In Vitro and In Vivo Antitumor Activity as a Potential Tool for Cancer Gene Therapy

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Cancer prevalence necessitates innovative therapies with reduced side effects.
• Gene therapy strategies are exploring suicide genes for direct tumor cell damage.
• The LdrB toxin from Escherichia coli is investigated as a potential cancer therapeutic agent.

Purpose of the Study:

• To evaluate the cytotoxic impact of the LdrB toxin from Escherichia coli k12 for cancer gene therapy.
• To assess the efficacy of LdrB gene expression in colorectal and breast cancer cells.
• To determine the safety and mechanism of action of LdrB as an antitumor agent.

Main Methods:

• Transfection of colorectal and breast cancer cells with the LdrB gene under a doxycycline-inducible promoter (TRE3G).
• In vitro proliferation assays using 2D and 3D cell culture models.
• In vivo studies in animal models to assess antitumor effects and side effects.
• Cell cycle analysis and scanning electron microscopy to elucidate the mechanism of action.

Main Results:

• LdrB gene expression significantly inhibited cancer cell proliferation in vitro and in vivo.
• The LdrB gene demonstrated potent antitumor activity without observable side effects in animal models.
• Antitumor effects were mediated by cell cycle arrest in the G0/G1 phase and induction of apoptotic cell death.
• LdrB toxin retained its pore-forming ability in human cancer cells, similar to its function in E. coli.

Conclusions:

• The LdrB gene from Escherichia coli exhibits significant potential as a novel suicide gene for cancer therapy.
• This study provides the first proof of concept for the antitumor capacity of the LdrB gene in colorectal and breast cancers.
• LdrB-based gene therapy represents a promising, side-effect-free approach to cancer treatment.